Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

January 13, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

January 13, 2025

From Ademi LLP

Via Business Wire

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On? ↗

January 13, 2025

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

Via Benzinga

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge ↗

January 13, 2025

Via Benzinga

Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews ↗

November 04, 2024

Via Benzinga

Earnings Preview For Intra-Cellular Therapies ↗

October 29, 2024

Via Benzinga

Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings) ↗

October 04, 2024

Via Benzinga

Expert Ratings For Intra-Cellular Therapies ↗

September 06, 2024

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)

January 13, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Nasdaq, S&P 500 Fall As Bond Yields Pressure Tech Stocks ↗

January 13, 2025

Stocks are a mixed bag to start the week.

Via Talk Markets

Topics Stocks Stocks / Equities

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗

January 13, 2025

Via Benzinga

Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings) ↗

August 07, 2024

Via Benzinga

A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies ↗

July 22, 2024

Via Benzinga

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗

January 13, 2025

Via Benzinga

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗

January 13, 2025

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

Via Benzinga

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal ↗

January 13, 2025

The deal values the smaller biotech company at a 39% premium to last week's closing price.

Via Investor's Business Daily

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders

January 13, 2025

From Halper Sadeh LLC

Via Business Wire

Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism ↗

January 13, 2025

ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million...

Via Stocktwits

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

January 13, 2025

From Johnson & Johnson

Via Business Wire

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

January 13, 2025

Via Benzinga

Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio? ↗

January 12, 2025

Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United...

Via Benzinga

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗

December 31, 2024

Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.

Via Benzinga

Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% ↗

November 05, 2024

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile.

Via Benzinga

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday ↗

September 06, 2024

Via Benzinga

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' ↗

August 07, 2024

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.

Via Investor's Business Daily

Topics Earnings

Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

August 06, 2024

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...

Via PressReach

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday ↗

July 22, 2024

Via Benzinga

China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio? ↗

June 23, 2024

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%).

Via Benzinga

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗

June 20, 2024

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.